Ann Trauma Acute Care | Volume 2, Issue 1 | Short Communication | Open Access

S100B and GFAP in Traumatic Brain Injury: A Pilot Study

Valentina Di Pietro^1,2,3* and Antonio Belli^1,2

¹Department of Neurotrauma and Ophthalmology, University of Birmingham, UK
²Department of Surgical Reconstruction and Microbiology, Queen Elizabeth Hospital, UK
³Department of Advanced Science and Technology, University of Illinois at Urbana-Champaign, USA

^*Correspondance to: Valentina Di Pietro 

Fulltext PDF

Abstract

Traumatic Brain Injury (TBI) is a leading cause of death and disability worldwide. There is great interest in the use of potential biomarkers of TBI for diagnosis, triage, prognostication and drug development. S100B and Glial Fibrillary Acid Protein (GFAP) are the most studied and candidate biomarkers of TBI. However, conflicting results hamper their routine application in clinical practice. In this study, serum samples of a small cohort of TBI patients at different severity and different time points from the injury were analysed by measuring the levels of S100B and GFAP.

Keywords:

Traumatic brain injury; Biomarkers; Diagnosis; S100B; GFAP

Citation:

Di Pietro V, Belli A. S100B and GFAP in Traumatic Brain Injury: A Pilot Study. Ann Trauma Acute Care. 2018; 2(1): 1006.